Florida / New York / No Carolina
Ph: 561.316.3330

New Study Demonstrates that Running Does Not Increase Risk of Arthritis

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • The participants were also asked if a doctor had ever advised them to stop or reduce their running, if they were still running at the time of questionnaire completion, and if they plan to run another marathon.
  • “Our multivariate analysis showed that the factors that increase a person’s risk for arthritis are the same for anyone with joint degeneration — whether or not they’re a runner.
  • “In fact, our survey showed that one in four people have received a recommendation by their physician to reduce their running volume, and for those with arthritis, nearly 50% of runners were told by their physicians to stop running altogether.

Chicago Marathon®participants helped orthopaedic researchers further understand the impact of long-distance running on bone and joint health, specifically knee and hip arthritis in recreational runners. Results from the largest survey of marathon runners ever conducted showed no association between cumulative running history and the risk for arthritis.

“Despite growing knowledge that running and being active can be healthy for your joints, there is a continued dogma among the healthcare community that patients should stop running to avoid wearing out their cartilage,” said lead author Matthew J. Hartwell, MD, an orthopaedic surgery sports medicine fellow at University of California San Francisco. “In fact, our survey showed that one in four people have received a recommendation by their physician to reduce their running volume, and for those with arthritis, nearly 50% of runners were told by their physicians to stop running altogether.”

Dr. Hartwell and his colleagues conducted the prospective cohort study, “Does Running Increase the Risk for Hip and Knee Arthritis? A Survey of 3,804 Chicago Marathon Runners,” during his residency at Northwestern University Feinberg School of Medicine in Chicago. It was presented at the 2023 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

The electronic survey was completed by 3,804 participants registered for the 2019 and 2021 Chicago Marathons. The mean age of respondents was 43.9. Participants had run an average of five or fewer marathons, and they had been running for an average of 14.7 years.

The survey featured 30 questions targeted at assessing:

  • Demographic information (age, sex, height, weight, country of origin and occupation)
  • Running history (number of years running; average weekly mileage over the past year; average running pace during training runs; number of marathons completed, including ultra-marathons; and participation with cross training)
  • Hip/knee health (occurrence of hip or knee pain over the past year that prevented running; a history of hip or knee injuries that required a break in running; a family history of hip and/or knee arthritis; surgical procedures performed on the hip or knee; and receiving a hip or knee arthritis diagnosis)

These data showed that the prevalence of hip and/or knee arthritis was 7.3%. Prior hip/knee injuries or surgery, advancing age, family history and BMI were risk factors for arthritis. Cumulative number of years running, number of marathons completed, weekly mileage and mean running pace proved not to be significant risk factors for arthritis.

“Our multivariate analysis showed that the factors that increase a person’s risk for arthritis are the same for anyone with joint degeneration — whether or not they’re a runner. Those factors include increase in age, BMI, a family history of hip or knee arthritis, and whether they’ve had injuries or knee surgery,” said Dr. Hartwell.

The participants were also asked if a doctor had ever advised them to stop or reduce their running, if they were still running at the time of questionnaire completion, and if they plan to run another marathon. The majority (94.2%) of runners planned to run another marathon despite 24.2% of all participants being told by a physician to do otherwise.

“Recreational runners are a dedicated group of people who use the sport for exercise, mental clarity or to challenge themselves,” said Vehniah K. Tjong, MD, FAAOS, associate professor of orthopaedic surgery at Northwestern University. “Our hope is these findings educate physicians, so they don’t instinctively advise against running and they work to meet patients on their level — because, as these data show, runners are likely to continue running despite medical advice.”

2023 AAOS Annual Meeting Disclosure Statement

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Updated Phase 2 CAPTIVATE Study Results

“After more than five years, the CAPTIVATE study findings confirm the sustained benefit of the fixed duration combination of ibrutinib and venetoclax as a first-line treatment for patients living with CLL, including in those with higher risk genomic features,” said Paolo Ghia MD, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy, study investigator.‡ “This all-oral, chemotherapy-free, fixed-duration regimen offers eligible patients the advantage of an extended, treatment-free interval while effectively keeping their disease under control.”

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

The VenusP-Valve PROTEUS STUDY, abbreviated from Evaluation of the PerfoRmance Of The VEnUsP-Valve System in Patients with Native Right Ventricular Outflow Tract (RVOT) Dysfunction, is a prospective multi-center non-randomized interventional study in patients with RVOT disorders comorbid with moderate or greater pulmonary regurgitation. With a target enrollment of 60 subjects, data from this trial will support VenusP-Valve's registration with the U.S. FDA and Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

Pfizer Reports | ELREXFIO ™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma

“These compelling overall survival data support the clinical benefit ELREXFIO has already demonstrated and its potential to be a transformative treatment option for people with multiple myeloma,” said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer. “The latest results from MagnetisMM-3 reinforce the very promising efficacy observed with ELREXFIO in a relapsed or refractory setting, with deep and durable responses and although definitive conclusions cannot be drawn across studies, the longest reported median progression-free survival among B-cell maturation antigen bispecific antibodies.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy